|
Phototherapy and Vitiligo
| #1 Narrow-band Ultraviolet B is a Useful and Well-Tolerated Treatment for Vitiligo Lubomira Scherschun, MD; Jane J. Kim, MD; Henry W. Lim, MD. Journal of American Academy of Dermatology. VOL 44, Number 6. June 2001 |
|
Seven diverse vitiligo patients treated for one year with narrow-band UVB therapy. Five of the seven achieved 75% repigmentation with a mean of 19 treatments.
CONCLUSION: Treatment protocol resulted in rapid repigmentation in many patients, including those with skin phototypes IV and V. In accordance with previous studies, this report indicates that narrow-band UVB is a useful and well-tolerated therapy for vitiligo. |
 |
|
#2 Treatment of Generalized Vitiligo in Children with Narrow-Band (TL-01) UVB Radiation Therapy. M. D. Njoo, MD, PhD and W. Westerhof, MD, PhD. Journal of American Academy of Dermatology. Vol 42, Number 2, Part 1. February 2000
|
|
Studied efficacy and safety of UVB (311 nm) therapy in children with generalized vitiligo. 51 Children were treated twice a week for one year. Psychosocial impact of disease and treatment were carefully evaluated before and after. 75% overall repigmentation in 53% of patients and a stabilization of the disease in 80%.
CONCLUSION: Narrow-band UVB therapy is effective and safe in childhood vitiligo; it may also significantly improve the quality of life. |
|
| #3 Narrow-band ultraviolet B treatment for vitiligo, pruritus, and inflammatory dermatoses. Samson Yashar S. Photodermatology, Photoimmunology & Photomedicine [Photodermatol Photoimmunol Photomed], 2003 Aug; Vol. 19 (4), pp. 164-8; PMID: 12925186 |
|
BACKGROUND: Narrow-band ultraviolet B (NB-UVB) therapy has been used successfully for the treatment of inflammatory and pigmentary skin disorders including atopic dermatitis, psoriasis, mycosis fungoides, polymorphous light eruption, and vitiligo. METHODS: This is a retrospective review of the treatment outcomes of 117 consecutive patients with vitiligo, pruritus, and other inflammatory dermatoses, excluding those with psoriasis and CTCL, who were treated with NB-UVB between 1998 and 2001 at our institution. RESULTS: Approximately 80% of all patients showed improvement in their condition. NB-UVB phototherapy was well tolerated, with no serious adverse effects. In patients with vitiligo, 6.4% had an abnormal thyroid-stimulating hormone level and 6.5% had anemia.
CONCLUSION: NB-UVB may be considered as a viable therapeutic option in the treatment of vitiligo, pruritus, and other inflammatory dermatoses. Long-term adverse effects and cost-benefit analysis of NB-UVB therapy compared to other treatment modalities remain to be determined.
|
|
